Use of the epidermal growth-factor receptor inhibitor erlotinib led to about a 30% reduction in duodenal polyp burden after 6 months of once-weekly treatment for patients with familial adenomatous ...

People with the hereditary disease familial adenomatous polyposis (FAP) have a greatly increased risk of developing a malignant tumor of the duodenum. Researchers have now discovered a mechanism in ...

The efficacy and safety of combination therapy with eflornithine and sulindac, as compared with either drug alone, in delaying disease progression in patients with familial adenomatous polyposis are ...

Familial adenomatous polyposis (FAP) is a hereditary disease which, in addition to carrying a high risk of bowel cancer, also greatly increases the risk of duodenal cancer. At present, the only ...

Undergoing cancer treatment at a younger age can put the survivors at risk of developing numerous gastrointestinal polyps, even if they do not have hereditary susceptibility to polyposis. The acquired ...

Here are the 2010 Medicare payment rates for six upper GI procedures in the ASC setting. 1. Upper GI endoscopy including esophagus, stomach and either duodenum and/or jejunum as appropriate; with ...